Current Trends in Control and Monitoring of Subvisible Particulate Matter in Biotherapeutics
Posted on June 23, 2026
Satish (Kumar) Singh, Vice President, Drug Product Development, Astria Therapeutics, Inc.
(previously Head of Drug Product Process Development, Lonza Pharma and Biotech, Basel, Switzerland)
Hanns-Christian Mahler, CEO & Board Member, ten23 health
(previously Head of Drug Product Services, Lonza Pharma and Biotech, Basel, Switzerland)
Particulate matter in the context of sterile parenteral products is a broad term that covers all manner of particles and agglomerates that may be found in the product. Particulate matter in sterile parenteral products is an undesirable characteristic, except in the case of sterile suspensions. Howev...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
